These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36097108)

  • 1. Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis.
    Demirtas Korkmaz F; Dogan Turacli I; Esendagli G; Ekmekci A
    Mol Biol Rep; 2022 Nov; 49(11):10387-10397. PubMed ID: 36097108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
    Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
    Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiostrepton confers protection against reactive oxygen species-related apoptosis by restraining FOXM1-triggerred development of gastric cancer.
    Liu SX; Zhou Y; Zhao L; Zhou LS; Sun J; Liu GJ; Du YS; Zhou YN
    Free Radic Biol Med; 2022 Nov; 193(Pt 1):385-404. PubMed ID: 36152915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
    Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
    J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
    Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
    Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
    Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
    Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression.
    Wang WD; Shang Y; Wang C; Ni J; Wang AM; Li GJ; Su L; Chen SZ
    Acta Pharmacol Sin; 2022 Nov; 43(11):2956-2966. PubMed ID: 35422085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.
    Maekawa A; Kohashi K; Setsu N; Kuda M; Iura K; Ishii T; Matsunobu T; Nakatsura T; Iwamoto Y; Oda Y
    Cancer Sci; 2016 Jan; 107(1):95-102. PubMed ID: 26560505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
    Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
    Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
    Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
    Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma.
    Jiang L; Wang P; Chen H
    Ups J Med Sci; 2014 Nov; 119(4):324-32. PubMed ID: 25231007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
    Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
    Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs.
    Guillen VS; Ziegler Y; Gopinath C; Kumar S; Dey P; Plotner BN; Dawson NZ; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Breast Cancer Res Treat; 2023 Apr; 198(3):607-621. PubMed ID: 36847915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
    Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
    BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.
    Lok GT; Chan DW; Liu VW; Hui WW; Leung TH; Yao KM; Ngan HY
    PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
    Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXM1: a new therapeutic target of extramammary Paget disease.
    Ito T; Tanaka Y; Kaku-Ito Y; Oda Y; Nakahara T
    Sci Rep; 2024 Feb; 14(1):4048. PubMed ID: 38374400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
    Katzenellenbogen BS; Guillen VS; Katzenellenbogen JA
    Breast Cancer Res; 2023 Jun; 25(1):76. PubMed ID: 37370117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.